We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+8.36%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
+$184M
Cap. Flow
+$269M
Cap. Flow %
24.82%
Top 10 Hldgs %
42.57%
Holding
126
New
25
Increased
29
Reduced
26
Closed
35

Top Buys

Rank Stock Value
1
TMCI icon
Treace Medical Concepts
TMCI
+$34.9M
2
TGTX icon
TG Therapeutics
TGTX
+$34.1M
3
GSK icon
GSK
GSK
+$33.5M
4
PODD icon
Insulet
PODD
+$28.6M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.8M

Top Sells

Rank Stock Value
1
CRL icon
Charles River Laboratories
CRL
+$23.3M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$13.7M
3
ACLX
Arcellx
ACLX
+$12.3M
4
CVS icon
CVS Health
CVS
+$11.5M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$9.95M

Sector Composition

Rank Sector Weight
1 Healthcare 90.02%
2 Consumer Staples 1.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANNX icon
76
Annexon
ANNX
$895M
$1.22M 0.11%
515,400
-105,000
-17% -$318K
LQDA icon
77
Liquidia Corp
LQDA
$7.9B
$1.11M 0.1%
175,000
– –
RCEL icon
78
Avita Medical
RCEL
$224M
$1.1M 0.1%
75,000
– –
KRTX
79
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$1.09M 0.1%
6,440
-7,700
-54% -$1.45M
AVDL
80
DELISTED
Avadel Pharmaceuticals
AVDL
$1.07M 0.1%
104,000
-203,000
-66% -$2.72M
ALPN
81
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.01M 0.09%
88,073
– –
YMAB
82
DELISTED
Y-mAbs Therapeutics
YMAB
$857K 0.08%
157,182
– –
APGE icon
83
Apogee Therapeutics
APGE
$10.2B
$746K 0.07%
+35,000
New +$771K
ALNY icon
84
Alnylam Pharmaceuticals
ALNY
$28.9B
$691K 0.06%
+3,900
New +$744K
DMRA
85
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.83B
$646K 0.06%
35,906
-4,094
-10% -$161K
DCTH icon
86
Delcath Systems
DCTH
$540M
$587K 0.05%
+144,958
New +$680K
SPRY icon
87
ARS Pharmaceuticals
SPRY
$600M
$567K 0.05%
+150,000
New +$985K
XERS icon
88
Xeris Biopharma Holdings
XERS
$1.34B
$566K 0.05%
304,083
-1,750,022
-85% -$4.01M
XLO icon
89
Xilio Therapeutics
XLO
$60.8M
$479K 0.04%
16,210
– –
IMUX icon
90
Immunic
IMUX
$211M
$441K 0.04%
30,000
– –
KROS icon
91
Keros Therapeutics
KROS
$213M
$405K 0.04%
12,700
-58,100
-82% -$2.17M
ACRS icon
92
Aclaris Therapeutics
ACRS
$842M
– –
-151,000
Closed -$1.57M
ADVM
93
DELISTED
Adverum Biotechnologies
ADVM
– –
-32,000
Closed -$509K
AMLX icon
94
Amylyx Pharmaceuticals
AMLX
$2.64B
– –
-120,000
Closed -$2.59M
ANGO icon
95
AngioDynamics
ANGO
$636M
– –
-768,500
Closed -$8.02M
BBIO icon
96
BridgeBio Pharma
BBIO
$16.3B
– –
-364,000
Closed -$6.26M
BDTX icon
97
Black Diamond Therapeutics
BDTX
$111M
– –
-435,000
Closed -$2.2M
BMRN icon
98
BioMarin Pharmaceuticals
BMRN
$12.3B
– –
-57,800
Closed -$5.01M
CLDX icon
99
Celldex Therapeutics
CLDX
$3.29B
– –
-13,600
Closed -$461K
CRSP icon
100
CRISPR Therapeutics
CRSP
$5.16B
– –
-42,400
Closed -$2.38M
2 3
4
5 6

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Soleus Capital Management held 126 positions worth $1.08B, up 20% from $900M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Soleus Capital Management deployed $269M of net new capital in Q3 2023, opening 25 new positions and adding to 29 existing holdings. Its largest new stake was Treace Medical Concepts: 1,907,823 shares worth $25M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 97% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Charles River Laboratories, an estimated $23.3M trimmed.

  • Soleus Capital Management's largest Q3 2023 buy was Treace Medical Concepts: 1,907,823 shares worth $25M.
  • Soleus Capital Management added most to TG Therapeutics in Q3 2023, an estimated $34.1M increase.
  • Soleus Capital Management's biggest Q3 2023 reduction was Charles River Laboratories, cutting an estimated $23.3M.
  • Soleus Capital Management fully exited Seagen Inc. Common Stock in Q3 2023, selling an estimated $13.7M.
  • Soleus Capital Management's ten largest holdings make up 43% of its $1.08B portfolio in Q3 2023.
  • Soleus Capital Management opened 25 new positions and closed 35 in Q3 2023.
  • Soleus Capital Management's portfolio value rose 20% quarter-over-quarter to $1.08B.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.